VivoSim Labs (VIVS)
Preclinical liver and intestinal toxicology testing with primary human tissue models.
Something off on this page? Send us feedback.
Provides project-based preclinical testing services using primary-human-cell liver and intestinal models, combining study design, assay data, and scientific interpretation for drug developers. Revenue is intended to come from contracted studies, alongside legacy patent royalties and contingent milestones from a divested drug program.
Builds NAMkind Liver and NAMkind Intestine/GI models from primary human cells for pharmaceutical and biotechnology customers evaluating drug safety, efficacy, and unexpected toxicology signals. Project-based services pair bespoke study design and modular assay panels with experimental data and scientific interpretation, spanning prospective screening, translational comparisons, and root-cause investigation.
Markets these services in the United States and Europe and uses distributors in parts of Asia-Pacific. Commercial adoption depends on customer acceptance of the models, reliable human-cell supply, and fit-for-purpose validation within evolving regulatory expectations; royalties from the BICO bioprinting patent license and contingent milestones from the divested drug program sit outside ordinary service work.
Company facts
Categories
No analyst consensus on record.
EPSReportedEstimate
RevenueReportedEstimate
Balance sheet, Jun 30, 2026Cash & short-term investments $1.7M · Total debt $316.0K · Total assets $3.8M · Shareholders' equity −$2.3M
- Revenue
- $18.0K
- Operating income
- −$2.8M
- Net income
- −$1.3M
No dividends on record.
| Institutions23 holders · as of Mar 31, 2026 | 0.66% | 97.9K shares | |
| Insiders6 holders · as of Sep 1, 2026 | 0.75% | 111.6K shares | |
| Otherremainder | 98.59% | 14.64M shares |
14.85M company shares as of Sep 3, 2026 · institutions as of Mar 31, 2026 · holders as of their latest filing
Two share counts disagree (14.85M in the company's Sep 3, 2026 report, 2.57M elsewhere); stakes use the report.
Top shareholders13F · 13D/G · Form 4
| Holder | Stake | Shares | Evidence |
|---|---|---|---|
Geode Capital Management, LLCInstitution | 0.25% | 36,850 | 13Fas of Mar 31, 2026 |
Keith MurphyInsiderdirector, officer: EXECUTIVE CHAIRMAN | 0.18% | 26,053 | Form 4filed Jan 29, 2026 ↗ |
Douglas Jay CohenInsiderdirector | 0.14% | 20,732 | Form 4filed Jan 29, 2026 ↗ |
Alison Tjosvold MilhousInsiderdirector | 0.13% | 19,899 | Form 4filed Jan 29, 2026 ↗ |
Adam K. SternInsiderdirector | 0.13% | 19,899 | Form 4filed Jan 29, 2026 ↗ |
| See all 25 → | |||
13F — a manager's quarterly holdings · Form 4 — an insider's transaction report
Insider tradesForm 4
| Date | Insider | Role | Shares | Avg price |
|---|---|---|---|---|
| Aug 31, 2026 | Tony Serge Lialin | officer: Chief Commercial Officer | +10,000 | $0.2804 |
| Nov 17, 2025 | David Gobel | director | −3,266 | $2.24 |
- Charles River Laboratories
Broad in-vitro CRO alternative for target-organ safety studies.
- Evotec (ADR)
Closest public 3D liver-microtissue and DILI-services alternative.
ComparePre-market
| Company | Price | Change | |||||
|---|---|---|---|---|---|---|---|
| VivoSim Labs | $0.2800 | +0.07% | $718.7K | — | — | 6.4 | −51.4% |
| Charles River Laboratories | $291.76 | +0.05% | $14.05B | — | 23.7 | 3.5 | −2.7% |
| Evotec (ADR) | $1.92 | +0.52% | $675.0M | — | — | 0.8 | −17.3% |
| Median | — | 23.7 | 2.2 | −10.0% |